ResearchMoz

Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity

GBI Research
Published Date » 2011-12-14
No. Of Pages » 156

GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity Description” which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2017. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. 

Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines.  The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented.

Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. 

Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 8.9% during the period 2010-2017 from $1,154.9m in 2010 to $2,095.9m by 2017. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies.

GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2010-2017. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts.

GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.

Scope

  • Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
  • Market forecasts for the seasonal influenza vaccines from 2010 to 2017
  • Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
  • Key drivers and restraints that have created significant impact on the market.
  • Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
  • Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
  • Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the seasonal influenza vaccine market.

Reasons to buy

  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.
Table of Contents

1 Table of Contents

1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 11

2 Seasonal Influenza Vaccine Market in Asia-Pacific Region - Introduction 14
2.1 GBI Research Report Guidance 15

3 Seasonal Influenza Vaccine Market in Asia-Pacific Region - Market Overview 16
3.1 Production Cycle for the Seasonal Influenza Vaccines 16
3.2 The Asia-Pacific Region Seasonal Influenza Vaccine Market 16
3.3 Revenue for the Seasonal Influenza Vaccine Market 17
3.4 Geographical Segmentation 19

4 Seasonal Influenza Vaccine Market in Asia-Pacific Region - Geographical Landscape 20
4.1 Australia 20
4.1.1 Vaccination Pattern 20
4.1.2 Cost of Vaccine 25
4.1.3 Total Revenue 26
4.2 New Zealand 28
4.2.1 Vaccination Pattern 28
4.2.2 Cost of Vaccine 33
4.2.3 Total Revenue 34
4.2.4 Major Players by Market Share 36
4.3 Taiwan 37
4.3.1 Vaccination Pattern 37
4.3.2 Cost of Vaccine 41
4.3.3 Total Revenue 42
4.3.4 Major Players by Market Share 44
4.4 Philippines 45
4.4.1 Vaccination Pattern 45
4.4.2 Cost of Vaccine 49
4.4.3 Total Revenue 50
4.4.4 Major Players by Market Share 52
4.5 Malaysia 53
4.5.1 Vaccination Pattern 53
4.5.2 Cost of Vaccine 57
4.5.3 Total Revenue 58
4.5.4 Major Players by Market Share 60
4.6 Hong Kong 61
4.6.1 Vaccination Pattern 61
4.6.2 Cost of Vaccine 65
4.6.3 Total Revenue 66
4.6.4 Major Players by Market Share 68
4.7 Singapore 69
4.7.1 Vaccination Pattern 69
4.7.2 Cost of Vaccine 73
4.7.3 Total Revenue 74
4.7.4 Major Players by Market Share 76
4.8 Japan 77
4.8.1 Vaccination Pattern 77
4.8.2 Cost of Vaccine 81
4.8.3 Total Revenue 82
4.8.4 Major Players in the Market 83
4.9 China 84
4.9.1 Vaccination Pattern 84
4.9.2 Cost of Vaccine 88
4.9.3 Total Revenue 89
4.9.4 Major Players in the Market 91
4.10 India 92
4.10.1 Vaccination Pattern 92
4.10.2 Cost of Vaccine 96
4.10.3 Total Revenue 97
4.10.4 Major Players in the Market 99

5 Seasonal Influenza Vaccine Market in Asia-Pacific Region - Drivers and Restraints 100
5.1 Drivers for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 100
5.1.1 Threat of Pandemic Influenza 100
5.1.2 Increasing Vaccination Coverage for Seasonal Influenza Vaccines 101
5.1.3 Emergence of Novel Production Technologies and Vaccines 104
5.1.4 Population Growth 105
5.1.5 Economic Reasons 105
5.2 Restraints for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 105
5.2.1 Entry Barriers in the Seasonal Influenza Vaccine Market 105
5.2.2 Variable Demand 106
5.2.3 Limited Production Capacity 106
5.3 Australia 106
5.3.1 Drivers 106
5.3.2 Restraints 106
5.4 New Zealand 107
5.4.1 Drivers 107
5.4.2 Restraints 107
5.5 Taiwan 107
5.5.1 Drivers 107
5.5.2 Restraints 107
5.6 Philippines 108
5.6.1 Drivers 108
5.6.2 Restraints 108
5.7 Malaysia 108
5.7.1 Drivers 108
5.7.2 Restraints 108
5.8 Hong Kong 109
5.8.1 Drivers 109
5.8.2 Restraints 109
5.9 Singapore 109
5.9.1 Drivers 109
5.9.2 Restraints 110
5.10 Japan 110
5.10.1 Drivers 110
5.10.2 Restraints 110
5.11 China 111
5.11.1 Drivers 111
5.11.2 Restraints 111
5.12 India 111
5.12.1 Drivers 111
5.12.2 Restraints 111

6 Seasonal Influenza Vaccine Market in Asia-Pacific Region - Regulatory Landscape 112
6.1 Registration Process and Regulations in Australia 112
6.2 Registration Process and Regulations in New Zealand 114
6.3 Registration Process and Regulations in Taiwan 117
6.4 Registration Process and Regulations in the Philippines 118
6.5 Registration Process and Regulations in Malaysia 120
6.6 Registration Process and Regulations in Hong Kong 122
6.7 Registration Process and Regulations in Singapore 123
6.8 Registration Process and Regulations in Japan 124
6.9 Registration Process and Regulations in China 126
6.10 Registration Process and Regulations in India 128

7 Seasonal Influenza Vaccine Market in Asia-Pacific Region - Pipeline Analysis 130
7.1 Seasonal Influenza Vaccines - Promising Vaccines under Clinical Development 130
7.2 Profiles for Promising Vaccines under Clinical Development 131
7.2.1 Optaflu 131
7.2.2 GSK2186877A 131
7.2.3 Intanza / Flu-ID 132
7.2.4 Fluad Pediatric 133
7.2.5 FluBlok 133
7.3 Research and Development Pipeline 134

8 Seasonal Influenza Vaccine Market in Asia-Pacific Region - Competitive Landscape 138
8.1 Major Seasonal Influenza Vaccines Marketed in the APAC Region 138
8.1.1 Fluarix 138
8.1.2 Vaxigrip 138
8.1.3 Influvac 138
8.1.4 Fluvax 138
8.1.5 Agrippal 138
8.2 Key Areas Focused for R&D 139
8.3 Competitive Profiling 140
8.3.1 Sanofi Pasteur 140
8.3.2 GlaxoSmithKline Biologicals 140
8.3.3 Abbott Laboratories (Solvay Pharmaceuticals) 140
8.3.4 CSL Biotherapies 140
8.3.5 Novartis Vaccines 141
8.3.6 Crucell N.V. (Berna Biotech) 141

9 Seasonal Influenza Vaccine Market in Asia-Pacific Region - M&A Landscape 142
9.1 Overview 142
9.2 Major Merger and Acquisition Deals, 2007-2011 142
9.2.1 AstraZeneca Acquires Medimmune 143
9.2.2 Sanofi-Aventis (now Sanofi) Acquires Acambis 143
9.2.3 Mymetics Acquires Virosome Biologicals 143
9.2.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock 143
9.2.5 Novartis Completes Acquisition of 85% Stake in Zhejiang Tianyuan 144
9.2.6 Abbott Laboratories Acquires Solvay Pharmaceuticals 144
9.2.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno 144
9.2.8 Johnson & Johnson Acquires Crucell 144
9.2.9 GlaxoSmithKline to Acquire Remaining Interest in Shenzhen GSK-Neptunus Biologicals 144
9.3 M&A Deals by Year of Completion, 2007-2011 145
9.4 M&A Deals by Geography 146
9.5 Major Licensing Agreements, 2007-2011 146
9.5.1 Crucell enters into License Agreement with Adimmune Corporation 146
9.5.2 MedImmune Enters into Licensing Agreement with Sanofi Pasteur 147
9.5.3 Vivalis enters into Licensing Agreement with GlaxoSmithKline 147
9.5.4 Vivalis enters into Licensing Agreement with Nobilon International 147
9.5.5 MedImmune enters into Licensing Agreement with GlaxoSmithKline 147
9.5.6 Hemispherx Biopharma Enters Into Licensing Agreement with BIKEN 147
9.5.7 MedImmune Enters Into Licensing Agreement with BIKEN 147
9.5.8 MedImmune Enters Into Licensing Agreement with Omninvest 148
9.5.9 OPKO Health Enters Into Licensing Agreement with Academia Sinica 148
9.5.10 AltraVax Enters Into Licensing Agreement with Maxygen 148
9.5.11 Protein Sciences Expands Its Licensing Agreement with UMN Pharma for FluBlok and PanBlok 148
9.5.12 NasVax Extends Its Research Agreement with Novartis 148
9.5.13 iBio Enters Into Licensing Agreement With G-Con 148
9.6 Licensing Deals by Year of Completion, 2007-2011 149
9.7 Licensing Deals by Geography 150

10 Seasonal Influenza Vaccine Market in Asia-Pacific Region - Appendix 151
10.1 Market Definitions 151
10.2 Abbreviations 151
10.3 Research Methodology 152
10.3.1 Coverage 152
10.3.2 The Scope of the Study 152
10.3.3 Secondary Research 153
10.3.4 Primary Research 153
10.3.5 Expert Panel Validation 155
10.4 Contact Us 156
10.5 Disclaimer 156
10.6 Sources 156

1.1 List of Tables

Table 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue, ($m), 2010-2017 17
Table 2: Seasonal Influenza Vaccine Market, Australia, Population (‘000), 2010-2017 20
Table 3: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Contribution by Age Groups (%), 2010-2017 21
Table 4: Seasonal Influenza Vaccine Market, Australia, Overall Vaccination Coverage (‘000), 2010 - 2017 23
Table 5: Seasonal Influenza Vaccine Market, Australia, Vaccination Coverage Break-up by Age Groups (‘000), 2010-2017 23
Table 6: Seasonal Influenza Vaccine Market, Australia, Overall Number of Doses (‘000), 2010-2017 23
Table 7: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Age Groups, (‘000), 2010-2017 24
Table 8: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Purchase Sector, (‘000), 2010-2017 25
Table 9: Seasonal Influenza Vaccine Market, Australia, Cost of Vaccine,($), 2010-2017 25
Table 10: Seasonal Influenza Vaccine Market, Australia, Revenue, ($m), 2010-2017 26
Table 11: Seasonal Influenza Vaccine Market, Australia, Revenue Breakdown, ($m), 2010-2017 27
Table 12: Seasonal Influenza Vaccine Market, New Zealand, Population (‘000), 2010-2017 28
Table 13: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution (%), 2010-2017 29
Table 14: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution by Age Groups (%), 2010-2017 29
Table 15: Seasonal Influenza Vaccine Market, New Zealand, Overall Vaccination Coverage (‘000), 2010-2017 31
Table 16: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Coverage by Age Groups (‘000), 2010-2017 31
Table 17: Seasonal Influenza Vaccine Market, New Zealand, Overall Number of Doses (‘000), 2010-2017 31
Table 18: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Age Groups (‘000), 2010-2017 32
Table 19: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Sector Contribution (‘000), 2010-2017 33
Table 20: Seasonal Influenza Vaccine Market, New Zealand Cost of Vaccine, ($), 2010-2017 33
Table 21: Seasonal Influenza Vaccine Market, New Zealand, Revenue, ($m), 2010-2017 34
Table 22: Seasonal Influenza Vaccine Market, New Zealand, Revenue Breakdown, ($m), 2010-2017 35
Table 23: Seasonal Influenza Vaccine Market, Taiwan, Population (‘000), 2010-2017 37
Table 24: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Contribution by Age Groups (%), 2010-2017 38
Table 25: Seasonal Influenza Vaccine Market, Taiwan, Overall Vaccination Coverage (‘000), 2010-2017 39
Table 26: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Coverage by Age Groups (‘000), 2010-2017 39
Table 27: Seasonal Influenza Vaccine Market, Taiwan, Overall Number of Doses (‘000), 2010-2017 39
Table 28: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Age Groups (‘000), 2010-2017 40
Table 29: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Sector Contribution (‘000), 2010-2017 41
Table 30: Seasonal Influenza Vaccine Market, Taiwan, Cost of Vaccine, ($), 2010-2017 41
Table 31: Seasonal Influenza Vaccine Market, Taiwan, Revenue, ($m), 2010-2017 42
Table 32: Seasonal Influenza Vaccine Market, Taiwan, Revenue Breakdown, ($m),  2010-2017 43
Table 33: Seasonal Influenza Vaccine Market, Philippines, Population (‘000), 2010-2017 45
Table 34: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Contribution by Age Groups (%), 2010-2017 46
Table 35: Seasonal Influenza Vaccine Market, Philippines, Overall Vaccination Coverage (‘000), 2010-2017 47
Table 36: Seasonal Influenza Vaccine Market, Philippines, Vaccination Coverage by Age Groups (‘000), 2010-2017 47
Table 37: Seasonal Influenza Vaccine Market, Philippines, Overall Number of Doses (‘000), 2010-2017 47
Table 38: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Age Groups (‘000), 2010-2017 48
Table 39: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Sector Contribution (‘000), 2010-2017 49
Table 40: Seasonal Influenza Vaccine Market, Philippines, Cost of Vaccine, ($), 2010-2017 49
Table 41: Seasonal Influenza Vaccine Market, Philippines, Revenue, ($m), 2010-2017 50
Table 42: Seasonal Influenza Vaccine Market, Philippines, Revenue Breakdown, ($m), 2010-2017 51
Table 43: Seasonal Influenza Vaccine Market, Malaysia, Population (‘000), 2010-2017 53
Table 44: Seasonal Influenza Vaccine Market, Malaysia, Overall Vaccinated Population Contribution (%), 2010-2017 54
Table 45: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Contribution by Age Groups (%), 2010-2017 54
Table 46: Seasonal Influenza Vaccine Market, Malaysia, Overall Vaccination Coverage (‘000), 2010-2017 55
Table 47: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Coverage by Age Groups (‘000), 2010-2017 55
Table 48: Seasonal Influenza Vaccine Market, Malaysia, Overall Number of Doses (‘000), 2010-2017 55
Table 49: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Age Groups (‘000), 2010-2017 56
Table 50: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Sector Contribution (‘000), 2010-2017 57
Table 51: Seasonal Influenza Vaccine Market, Malaysia, Cost of Vaccine, ($), 2010-2017 57
Table 52: Seasonal Influenza Vaccine Market, Malaysia, Revenue, ($m), 2010-2017 58
Table 53: Seasonal Influenza Vaccine Market, Malaysia, Revenue Breakdown, ($m),  2010-2017 59
Table 54: Seasonal Influenza Vaccine Market, Hong Kong, Population (‘000), 2010-2017 61
Table 55: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Contribution by Age Groups (%), 2010-2017 62
Table 56: Seasonal Influenza Vaccine Market, Hong Kong, Overall Vaccination Coverage (‘000), 2010-2017 63
Table 57: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Coverage by Age Groups (‘000), 2010-2017 63
Table 58: Seasonal Influenza Vaccine Market, Hong Kong, Overall Number of Doses (‘000), 2010-2017 63
Table 59: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Age Groups (‘000), 2010-2017 64
Table 60: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Sector Contribution (‘000), 2010-2017 65
Table 61: Seasonal Influenza Vaccine Market, Hong Kong, Cost of Vaccine, ($), 2010-2017 65
Table 62: Seasonal Influenza Vaccine Market, Hong Kong, Revenue, ($m), 2010-2017 66
Table 63: Seasonal Influenza Vaccine Market, Hong Kong, Revenue Breakdown, ($m), 2010-2017 67
Table 64: Seasonal Influenza Vaccine Market, Singapore, Population (‘000), 2010-2017 69
Table 65: Seasonal Influenza Vaccine Market, Singapore, Overall Vaccinated Population Contribution (%), 2010-2017 70
Table 66: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Contribution by Age Groups (%), 2010-2017 70
Table 67: Seasonal Influenza Vaccine Market, Singapore, Overall Vaccination Coverage (‘000), 2010-2017 71
Table 68: Seasonal Influenza Vaccine Market, Singapore, Vaccination Coverage by Age Groups (‘000), 2010-2017 71
Table 69: Seasonal Influenza Vaccine Market, Singapore, Overall Number of Doses (‘000), 2010-2017 71
Table 70: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Age Groups (‘000), 2010-2017 72
Table 71: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Sector Contribution (‘000), 2010-2017 73
Table 72: Seasonal Influenza Vaccine Market, Singapore, Cost of Vaccine, ($), 2010-2017 73
Table 73: Seasonal Influenza Vaccine Market, Singapore, Revenue, ($m), 2010-2017 74
Table 74: Seasonal Influenza Vaccine Market, Singapore, Revenue Breakdown, ($m), 2010-2017 75
Table 75: Seasonal Influenza Vaccine Market, Japan, Population (‘000), 2010-2017 77
Table 76: Seasonal Influenza Vaccine Market, Japan, Vaccinated Population Contribution by Age Group (%), 2010-2017 78
Table 77: Seasonal Influenza Vaccine Market, Japan, Overall Vaccination Coverage (‘000), 2010-2017 79
Table 78: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage Break-up by Age Group (‘000), 2010-2017 79
Table 79:  Seasonal Influenza Vaccine Market, Japan, Overall Number of Doses (‘000), 2010-2017 79
Table 80: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Age Group, (‘000), 2010-2017 80
Table 81: Seasonal Influenza Vaccine Market, Japan, Cost of Vaccine, ($), 2010-2017 81
Table 82: Seasonal Influenza Vaccine Market, Japan, Revenue, ($m), 2010-2017 82
Table 83: Seasonal Influenza Vaccine Market, China, Population (‘000), 2010 - 2017 84
Table 84: Seasonal Influenza Vaccine Market, China, Vaccinated Population Contribution by Age Group (%), 2010-2017 85
Table 85: Seasonal Influenza Vaccine Market, China, Overall Vaccination Coverage (‘000),  2010-2017 86
Table 86: Seasonal Influenza Vaccine Market, China, Vaccination Coverage by Age Group (‘000), 2010-2017 86
Table 87: Seasonal Influenza Vaccine Market, China, Overall Number of Doses (‘000),  2010-2017 86
Table 88: Seasonal Influenza Vaccine Market, China, Number of Doses by Age Groups (‘000), 2010-2017 87
Table 89: Seasonal Influenza Vaccine Market, China, Cost of Vaccine ($), 2010-2017 88
Table 90: Seasonal Influenza Vaccine Market, China, Revenue, ($m), 2010-2017 89
Table 91: Seasonal Influenza Vaccine Market, China, Revenue Breakdown, ($m),  2010-2017 90
Table 92: Seasonal Influenza Vaccine Market, India, Vaccinated Population Contribution by Age Groups (%), 2010-2017 93
Table 93: Seasonal Influenza Vaccine Market, India, Overall Vaccination Coverage (‘000), 2010-2017 94
Table 94: Seasonal Influenza Vaccine Market, India, Vaccination Coverage by Age Group (‘000), 2010-2017 94
Table 95: Seasonal Influenza Vaccine Market, India, Overall Number of Doses (‘000), 2010-2017 94
Table 96: Seasonal Influenza Vaccine Market, India, Number of Doses by Age Group (‘000), 2010-2017 95
Table 97: Seasonal Influenza Vaccine Market, India, Cost of Vaccine($), 2010-2017 96
Table 98: Seasonal Influenza Vaccine Market, India, Revenue, ($m), 2010-2017 97
Table 99: Seasonal Influenza Vaccine Market, India, Revenue Breakdown, ($m),  2010-2017 98
Table 100: Seasonal Influenza Vaccine Market, Increasing Vaccination Coverage Against Seasonal Influenza. 2010-2017 102
Table 101: Seasonal Influenza Vaccine Market, Vaccination Coverage Rate, (%),  2010-2017 103
Table 102: Seasonal Influenza Vaccine Market, Most Promising Vaccines Under Clinical Development, 2011 130
Table 103: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Pipeline, Filed, 2011 134
Table 104: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Phase III Clinical Pipeline, 2011 135
Table 105: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Phase II Clinical Pipeline, 2011 135
Table 106: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Phase I Clinical Pipeline, 2011 136
Table 107: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Pre-Clinical Pipeline, 2011 137
Table 108: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Discovery Phase Pipeline, 2011 137
Table 109: Seasonal Influenza Vaccine Market, Asia-Pacific, Major M&A Deals, 2007-2011 142

1.2 List of Figures

Figure 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue, ($m), 2010-2017 16
Figure 2: Seasonal Influenza Vaccine Market, APAC Region, Market Share by Country (%), 2010 and 2017 18
Figure 3: Seasonal Influenza Vaccine Market, Australia, Population (‘000), 2010-2017 19
Figure 4: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Contribution by Age Groups (%), 2010-2017 20
Figure 5: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Age Groups, (‘000), 2010-2017 23
Figure 6: Seasonal Influenza Vaccine Market, Australia, Revenue, ($m), 2010-2017 25
Figure 7: Seasonal Influenza Vaccine Market, Australia, Revenue Breakdown, ($m), 2010-2017 26
Figure 8: Seasonal Influenza Vaccine Market, New Zealand, Population (‘000), 2010-2017 27
Figure 9: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution by Age Groups (%), 2010-2017 28
Figure 10: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Age Groups (‘000), 2010-2017 31
Figure 11: Seasonal Influenza Vaccine Market, New Zealand, Revenue, ($m), 2010-2017 33
Figure 12: Seasonal Influenza Vaccine Market, New Zealand, Revenue Breakdown, ($m), 2010-2017 34
Figure 13: Seasonal Influenza Vaccine Market, New Zealand, Market Share by Company (%), 2010 35
Figure 14: Seasonal Influenza Vaccine Market, Taiwan, Population (‘000), 2010-2017 36
Figure 15: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Contribution by Age Groups (%), 2010-2017 37
Figure 16: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Age Groups (‘000), 2010-2017 39
Figure 17: Seasonal Influenza Vaccine Market, Taiwan, Revenue, ($m), 2010-2017 41
Figure 18: Seasonal Influenza Vaccine Market, Taiwan, Revenue Breakdown, ($m),  2010-2017 42
Figure 19: Seasonal Influenza Vaccine Market, Taiwan, Market Share by Company, (%), 2010 43
Figure 20: Seasonal Influenza Vaccine Market, Philippines, Population (‘000), 2010-2017 44
Figure 21: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Contribution by Age Groups (%), 2010-2017 45
Figure 22: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Age Groups (‘000), 2010-2017 47
Figure 23: Seasonal Influenza Vaccine Market, Philippines, Revenue, ($m), 2010-2017 49
Figure 24: Seasonal Influenza Vaccine Market, Philippines, Revenue Breakdown, ($m), 2010-2017 50
Figure 25: Seasonal Influenza Vaccine Market, Philippines, Market Share by Company, (%), 2010 51
Figure 26: Seasonal Influenza Vaccine Market, Malaysia, Population (‘000), 2010-2017 52
Figure 27: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Contribution by Age Groups (%), 2010-2017 53
Figure 28: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Age Groups (‘000), 2010-2017 55
Figure 29: Seasonal Influenza Vaccine Market, Malaysia, Revenue, ($m), 2010-2017 57
Figure 30: Seasonal Influenza Vaccine Market, Malaysia, Revenue Breakdown, ($m),  2010-2017 58
Figure 31: Seasonal Influenza Vaccine Market, Malaysia, Market Share by Company, (%), 2010 59
Figure 32: Seasonal Influenza Vaccine Market, Hong Kong, Population (‘000), 2010-2017 60
Figure 33: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Contribution by Age Groups (%), 2010-2017 61
Figure 34: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Age Groups (‘000), 2010-2017 63
Figure 35: Seasonal Influenza Vaccine Market, Hong Kong, Revenue, ($m), 2010-2017 65
Figure 36: Seasonal Influenza Vaccine Market, Hong Kong, Revenue Breakdown, ($m), 2010-2017 66
Figure 37: Seasonal Influenza Vaccine Market, Hong Kong, Market Share by Company, (%), 2010 67
Figure 38: Seasonal Influenza Vaccine Market, Singapore, Population (‘000), 2010-2017 68
Figure 39: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Contribution by Age Groups (%), 2010-2017 69
Figure 40: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Age Groups (‘000), 2010-2017 71
Figure 41: Seasonal Influenza Vaccine Market, Singapore, Revenue, ($m), 2010-2017 73
Figure 42: Seasonal Influenza Vaccine Market, Singapore, Revenue Breakdown, ($m),  2010-2017 74
Figure 43: Seasonal Influenza Vaccine Market, Singapore, Market Share by Company, (%), 2010 75
Figure 44: Seasonal Influenza Vaccine Market, Japan, Population (‘000), 2010-2017 76
Figure 45: Seasonal Influenza Vaccine Market, Japan, Vaccinated Population Contribution by Age Group (%), 2010-2017 77
Figure 46: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Age Group, (‘000), 2010-2017 79
Figure 47: Seasonal Influenza Vaccine Market, Japan, Revenue, ($m), 2010-2017 81
Figure 48: Seasonal Influenza Vaccine Market, Japan, Major Players in the Market, 2010 82
Figure 49: Seasonal Influenza Vaccine Market, China, Population (‘000), 2010 - 2017 83
Figure 50: Seasonal Influenza Vaccine Market, China, Vaccinated Population Contribution by Age Group (%), 2010-2017 84
Figure 51: Seasonal Influenza Vaccine Market, China, Number of Doses by Age Group (‘000), 2010-2017 86
Figure 52: Seasonal Influenza Vaccine Market, China, Revenue, ($m), 2010-2017 88
Figure 53: Seasonal Influenza Vaccine Market, China, Revenue Breakdown, ($m), 2010-2017 89
Figure 54: Seasonal Influenza Vaccine Market, China, Major Players in the Market, 2010 90
Figure 55: Seasonal Influenza Vaccine Market, India, Population (Thousands), 2010-2017 91
Figure 56: Seasonal Influenza Vaccine Market, India, Vaccinated Population Contribution by Age Groups (%), 2010-2017 92
Figure 57: Seasonal Influenza Vaccine Market, India, Number of Doses by Age Group (‘000), 2010-2017 94
Figure 58: Seasonal Influenza Vaccine Market, India, Revenue, ($m), 2010-2017 96
Figure 59: Seasonal Influenza Vaccine Market, India, Revenue Breakdown, ($m), 2010-2017 97
Figure 60: Seasonal Influenza Vaccine Market, India, Major Players in the Market, 2010 98
Figure 61: Seasonal Influenza Vaccine Market, APAC Region, Drivers and Restraints,  2010-2017 99
Figure 62: Seasonal Influenza Vaccine Market, Increasing Vaccination Coverage Against Seasonal Influenza. 2010-2017 100
Figure 63: Seasonal Influenza Vaccine Market, Vaccination Coverage Rate, (%), 2010-2017 102
Figure 64: Seasonal Influenza Vaccine Market, Regulatory Authorities in Australia, 2011 111
Figure 65: Seasonal Influenza Vaccine Market, Drug Approval Process in Australia, 2011 111
Figure 66: Seasonal Influenza Vaccine Market, Regulatory Authorities in New Zealand, 2011 113
Figure 67: Seasonal Influenza Vaccine Market, Drug Approval Process in New Zealand, 2011 113
Figure 68: Seasonal Influenza Vaccine Market, Regulatory Authorities in Taiwan, 2011 116
Figure 69: Seasonal Influenza Vaccine Market, Drug Approval Process in Taiwan, 2011 116
Figure 70: Seasonal Influenza Vaccine Market, Regulatory Authorities in the Philippines, 2011 117
Figure 71: Seasonal Influenza Vaccine Market, Drug Approval Process in Philippines, 2011 117
Figure 72: Seasonal Influenza Vaccine Market, Regulatory Authorities in Malaysia, 2011 119
Figure 73: Seasonal Influenza Vaccine Market, Drug Approval Process in Malaysia, 2011 120
Figure 74: Seasonal Influenza Vaccine Market, Regulatory Authorities in Hong Kong, 2011 121
Figure 75: Seasonal Influenza Vaccine Market, Drug Approval Process in Hong Kong, 2011 121
Figure 76: Seasonal Influenza Vaccine Market, Regulatory Authorities in Singapore, 2011 122
Figure 77: Seasonal Influenza Vaccine Market, Drug Approval Process in Singapore, 2011 122
Figure 78: Seasonal Influenza Vaccine Market, Regulatory Authorities in Japan, 2011 123
Figure 79: Seasonal Influenza Vaccine Market, Drug Approval Process in Japan, 2011 124
Figure 80: Seasonal Influenza Vaccine Market, Regulatory Authorities in China, 2011 125
Figure 81: Seasonal Influenza Vaccine Market, Drug Approval Process in China for New Drug Registration Process, 2011 125
Figure 82: Seasonal Influenza Vaccine Market, Regulatory Authority in India, 2011 127
Figure 83: Seasonal Influenza Vaccine Market, Common Technical Document, India, 2011 127
Figure 84: Seasonal Influenza Vaccine Market, Drug Approval Process in India, 2011 128
Figure 85: Seasonal Influenza Vaccine Market, Asia-Pacific Region, R&D Pipeline by Phase (%), 2011 133
Figure 86: Seasonal Influenza Vaccine Market, Product Pipeline of Major Players in Asia-Pacific Region, 2011 138
Figure 87: Seasonal Influenza Vaccine Market, Completed M&A Deals by Year, 2007-2011 144
Figure 88: Seasonal Influenza Vaccine Market, M&A Deals by Geography, (%), 2007-2011 145
Figure 89: Seasonal Influenza Vaccine Market, Completed R&D Deals by Year, 2007-2011 148
Figure 90: Seasonal Influenza Vaccine Market, Licensing Agreements by Geography, (%), 2007-2011 149
Figure 91: GBI Research Market Forecasting Model, Estimation of Market for Taiwan, $m, 2010 154

List of Tables


List of Figures

Upcoming Reports:

Endocrine, Nutritional, & Metabolic Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020
By - Transparency Market Research
Endocrine, Nutritional, & Metabolic Disorders include diseases that affect endocrine glands (thyroid, parathyroid, pituitary, adrenals, thymus, islets of pancreas, ovaries and testicles), nutritional deficiencies such as malnutrition and vitamin deficiencies, and metabolism disorders such related  lipid metabolism, carbohydrate metabolism, amino acid metabolism, plasma protein metabolism and other metabolic disorders. Endocrine glands release specific hormones in the blood stream which help in coordinating and controlling several physiological processes in the body. An...
Poland: washing machines market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the washing machines market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the washing machines market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate...
Organic Beverages Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts, 2012 - 2018
By - Transparency Market Research
The organic beverages market is an upcoming sector as people are now beginning to focus their attention on organic beverages rather than carbonated functional drinks. Organic beverages offer a number of health benefits. Rising concerns of people over health issues is fuelling the growth of organic beverages. Rising interest in organic soda without artificial flavorings and preservatives is, no doubt, in demand today. People prefer organic beverages over drinks that are high in sugar, full of chemicals and lack nutritional value. All these factors together are fuelling the demand of...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...